Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 14/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2336357 | 0.94 | PTGDR2 (0.75) | PTGDR2SMN1; SMN2PKMTSHRPTGDR | |
| SCHEMBL2335093 | 0.92 | PTGDR2 (0.67) | PTGDR2PTGDRTP53 | |
| SCHEMBL2339161 | 0.89 | PTGDR2 (0.77) | PTGDR2TSHRPTGDR | |
| SCHEMBL2335302 | 0.86 | PTGDR2 (0.56) | PTGDR2PTGDR | |
| SCHEMBL2335485 | 0.86 | PTGDR2 (0.56) | PTGDR2PTGDR | |
| SCHEMBL2331725 | 0.86 | PTGDR2 (0.56) | PTGDR2PTGDR | |
| SCHEMBL2334034 | 0.84 | PTGDR2 (0.58) | PTGDR2PKM | |
| SCHEMBL2333511 | 0.84 | PTGDR2 (0.55) | PTGDR2PTGDR | |
| SCHEMBL13363604 | 0.84 | PTGDR2 (0.57) | PTGDR2PKMTSHRPTGDR | |
| SCHEMBL2337057 | 0.83 | PTGDR2 (0.54) | PTGDR2PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188090-B2 | Naphthylacetic acids | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | claimed |
| US-20100125061-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-05-20 | — | — | US | claimed |
| EP-2358677-B1 | NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| EP-2358677-B1 | NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-8188090-B2 | Naphthylacetic acids | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188090-B2 | Naphthylacetic acids | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188090-B2 | Naphthylacetic acids | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2358677-A1 | NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-08-24 | — | — | EP | disclosed |
| US-20100125061-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-05-20 | — | — | US | disclosed |
| US-20100125061-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-05-20 | — | — | US | disclosed |
| US-20100125061-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-05-20 | — | — | US | disclosed |
| WO-2010055006-A1 | NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010055006-A1 | NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125061-A1 | NAPHTHYLACETIC ACIDS | HRH2, HRH1, HRH3 | PTGDR2 32/4885SMN1; SMN2 3890/4885PKM 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.